Non-Small Cell Lung Cancer

1st line

Squamous

IRB# 21821 CodeBreak 101:
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

IRB# 23575 NIT-119:
A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

Non-squamous

2nd/3rd Line

Squamous

IRB# 21821 CodeBreak 101:
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

IRB# 23575 NIT-119:
A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

Non-squamous

Cross-Disease Trials:

IRB# 18094 S1609 (DART)
IRB# 19992 MATCH:
IRB# 21325 RGX-104

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

For more information, visit: https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result